M&A Deal Summary |
|
|---|---|
| Date | 2011-01-26 |
| Target | CyDex Pharmaceuticals |
| Sector | Life Science |
| Buyer(s) | Ligand Pharmaceuticals |
| Deal Type | Add-on Acquisition |
| Deal Value | 31M USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1987 |
| Sector | Life Science |
| Employees | 68 |
| Revenue | 167M USD (2024) |
Ligand Pharmaceuticals is a pharmaceutical company, develops products for men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases. Ligand Pharmaceuticals was founded in 1987 and is based in Jupiter, Florida.
| DEAL STATS | # |
|---|---|
| Overall | 4 of 16 |
| Sector: Life Science M&A | 4 of 15 |
| Type: Add-on Acquisition M&A Deals | 4 of 13 |
| State: Kansas M&A | 1 of 1 |
| Country: United States M&A | 4 of 14 |
| Year: 2011 M&A | 1 of 1 |
| Size (of disclosed) | 6 of 14 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2009-10-27 |
Metabasis Therapeutics
La Jolla, California, United States Metabasis Therapeutics, Inc. is a biopharmaceutical company that has discovered novel drugs for metabolic diseases using its proprietary technology and its knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-12-17 |
Open Monoclonal Technology
Palo Alto, California, United States Open Monoclonal Technology, Inc. (OMT) is a biotechnological company provides genetic engineering of animals for discovery of human therapeutic antibodies, naturally optimized human antibodies® and the only company with three transgenic animal platforms, collectively known as OmniAb™. All OmniAb platforms — OmniRat®, OmniMouse®, and OmniFlic™ — have broad freedom to operate, are protected by new patents and patent applications, and are available for all targets and indications |
Buy | $178M |
